The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome.
Neuroreport
; 3(7): 637-40, 1992 Jul.
Article
em En
| MEDLINE
| ID: mdl-1421123
ABSTRACT
Considerable evidence has accumulated to suggest that intracerebroventricular administration of enkephalinase inhibitors, which do not penetrate the blood-brain barrier, significantly attenuates opioid withdrawal syndrome. Therefore, the aim of this study was to examine the effect of intraperitoneal (i.p.) administration of orally active enkephalinase inhibitors, acetorphan (2.5-20 mg kg-1) and SCH 34826 (15-120 mg kg-1). These drugs significantly decreased the severity of the naloxone precipitated withdrawal syndrome in morphine dependent rats and mice. It therefore appears that these orally active enkephalinase inhibitors are promising tools in studying modulation of opioid dependence phenomena.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Comportamento Estereotipado
/
Síndrome de Abstinência a Substâncias
/
Neprilisina
/
Tiorfano
/
Dioxolanos
/
Dipeptídeos
/
Analgésicos
/
Morfina
/
Dependência de Morfina
Limite:
Animals
Idioma:
En
Revista:
Neuroreport
Assunto da revista:
NEUROLOGIA
Ano de publicação:
1992
Tipo de documento:
Article
País de afiliação:
Holanda